Intestinal Alkaline Phosphatase Attenuates Alcohol-Induced Hepatosteatosis in Mice. 2017

Sulaiman R Hamarneh, and Byeong-Moo Kim, and Kanakaraju Kaliannan, and Sara A Morrison, and Tyler J Tantillo, and Qingsong Tao, and Mussa M Rafat Mohamed, and Juan M Ramirez, and Aaron Karas, and Wei Liu, and Dong Hu, and Abeba Teshager, and Sarah Shireen Gul, and Konstantinos P Economopoulos, and Atul K Bhan, and Madhu S Malo, and Michael Y Choi, and Richard A Hodin
Department of Surgery, Harvard Medical School, Massachusetts General Hospital, 15 Parkman Street, Boston, MA, 02114, USA.

Bacterially derived factors from the gut play a major role in the activation of inflammatory pathways in the liver and in the pathogenesis of alcoholic liver disease. The intestinal brush-border enzyme intestinal alkaline phosphatase (IAP) detoxifies a variety of bacterial pro-inflammatory factors and also functions to preserve gut barrier function. The aim of this study was to investigate whether oral IAP supplementation could protect against alcohol-induced liver disease. Mice underwent acute binge or chronic ethanol exposure to induce alcoholic liver injury and steatosis ± IAP supplementation. Liver tissue was assessed for biochemical, inflammatory, and histopathological changes. An ex vivo co-culture system was used to examine the effects of alcohol and IAP treatment in regard to the activation of hepatic stellate cells and their role in the development of alcoholic liver disease. Pretreatment with IAP resulted in significantly lower serum alanine aminotransferase compared to the ethanol alone group in the acute binge model. IAP treatment attenuated the development of alcohol-induced fatty liver, lowered hepatic pro-inflammatory cytokine and serum LPS levels, and prevented alcohol-induced gut barrier dysfunction. Finally, IAP ameliorated the activation of hepatic stellate cells and prevented their lipogenic effect on hepatocytes. IAP treatment protected mice from alcohol-induced hepatotoxicity and steatosis. Oral IAP supplementation could represent a novel therapy to prevent alcoholic-related liver disease in humans.

UI MeSH Term Description Entries
D007422 Intestines The section of the alimentary canal from the STOMACH to the ANAL CANAL. It includes the LARGE INTESTINE and SMALL INTESTINE. Intestine
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D010539 Permeability Property of membranes and other structures to permit passage of light, heat, gases, liquids, metabolites, and mineral ions. Permeabilities
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D005235 Fatty Liver, Alcoholic Lipid infiltration of the hepatic parenchymal cells that is due to ALCOHOL ABUSE. The fatty changes in the alcoholic fatty liver may be reversible, depending on the amounts of TRIGLYCERIDES accumulated. Alcoholic Fatty Liver,Alcoholic Steatohepatitis
D005260 Female Females
D000410 Alanine Transaminase An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2. Alanine Aminotransferase,Glutamic-Pyruvic Transaminase,SGPT,Alanine-2-Oxoglutarate Aminotransferase,Glutamic-Alanine Transaminase,Alanine 2 Oxoglutarate Aminotransferase,Aminotransferase, Alanine,Aminotransferase, Alanine-2-Oxoglutarate,Glutamic Alanine Transaminase,Glutamic Pyruvic Transaminase,Transaminase, Alanine,Transaminase, Glutamic-Alanine,Transaminase, Glutamic-Pyruvic
D000431 Ethanol A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in ALCOHOLIC BEVERAGES. Alcohol, Ethyl,Absolute Alcohol,Grain Alcohol,Alcohol, Absolute,Alcohol, Grain,Ethyl Alcohol

Related Publications

Sulaiman R Hamarneh, and Byeong-Moo Kim, and Kanakaraju Kaliannan, and Sara A Morrison, and Tyler J Tantillo, and Qingsong Tao, and Mussa M Rafat Mohamed, and Juan M Ramirez, and Aaron Karas, and Wei Liu, and Dong Hu, and Abeba Teshager, and Sarah Shireen Gul, and Konstantinos P Economopoulos, and Atul K Bhan, and Madhu S Malo, and Michael Y Choi, and Richard A Hodin
July 2005, Infection and immunity,
Sulaiman R Hamarneh, and Byeong-Moo Kim, and Kanakaraju Kaliannan, and Sara A Morrison, and Tyler J Tantillo, and Qingsong Tao, and Mussa M Rafat Mohamed, and Juan M Ramirez, and Aaron Karas, and Wei Liu, and Dong Hu, and Abeba Teshager, and Sarah Shireen Gul, and Konstantinos P Economopoulos, and Atul K Bhan, and Madhu S Malo, and Michael Y Choi, and Richard A Hodin
May 2021, Circulation research,
Sulaiman R Hamarneh, and Byeong-Moo Kim, and Kanakaraju Kaliannan, and Sara A Morrison, and Tyler J Tantillo, and Qingsong Tao, and Mussa M Rafat Mohamed, and Juan M Ramirez, and Aaron Karas, and Wei Liu, and Dong Hu, and Abeba Teshager, and Sarah Shireen Gul, and Konstantinos P Economopoulos, and Atul K Bhan, and Madhu S Malo, and Michael Y Choi, and Richard A Hodin
April 2013, Proceedings of the National Academy of Sciences of the United States of America,
Sulaiman R Hamarneh, and Byeong-Moo Kim, and Kanakaraju Kaliannan, and Sara A Morrison, and Tyler J Tantillo, and Qingsong Tao, and Mussa M Rafat Mohamed, and Juan M Ramirez, and Aaron Karas, and Wei Liu, and Dong Hu, and Abeba Teshager, and Sarah Shireen Gul, and Konstantinos P Economopoulos, and Atul K Bhan, and Madhu S Malo, and Michael Y Choi, and Richard A Hodin
January 1957, Hoppe-Seyler's Zeitschrift fur physiologische Chemie,
Sulaiman R Hamarneh, and Byeong-Moo Kim, and Kanakaraju Kaliannan, and Sara A Morrison, and Tyler J Tantillo, and Qingsong Tao, and Mussa M Rafat Mohamed, and Juan M Ramirez, and Aaron Karas, and Wei Liu, and Dong Hu, and Abeba Teshager, and Sarah Shireen Gul, and Konstantinos P Economopoulos, and Atul K Bhan, and Madhu S Malo, and Michael Y Choi, and Richard A Hodin
November 2003, Molecular and cellular biology,
Sulaiman R Hamarneh, and Byeong-Moo Kim, and Kanakaraju Kaliannan, and Sara A Morrison, and Tyler J Tantillo, and Qingsong Tao, and Mussa M Rafat Mohamed, and Juan M Ramirez, and Aaron Karas, and Wei Liu, and Dong Hu, and Abeba Teshager, and Sarah Shireen Gul, and Konstantinos P Economopoulos, and Atul K Bhan, and Madhu S Malo, and Michael Y Choi, and Richard A Hodin
January 2022, Frontiers in immunology,
Sulaiman R Hamarneh, and Byeong-Moo Kim, and Kanakaraju Kaliannan, and Sara A Morrison, and Tyler J Tantillo, and Qingsong Tao, and Mussa M Rafat Mohamed, and Juan M Ramirez, and Aaron Karas, and Wei Liu, and Dong Hu, and Abeba Teshager, and Sarah Shireen Gul, and Konstantinos P Economopoulos, and Atul K Bhan, and Madhu S Malo, and Michael Y Choi, and Richard A Hodin
July 1955, Archivio italiano di scienze farmacologiche,
Sulaiman R Hamarneh, and Byeong-Moo Kim, and Kanakaraju Kaliannan, and Sara A Morrison, and Tyler J Tantillo, and Qingsong Tao, and Mussa M Rafat Mohamed, and Juan M Ramirez, and Aaron Karas, and Wei Liu, and Dong Hu, and Abeba Teshager, and Sarah Shireen Gul, and Konstantinos P Economopoulos, and Atul K Bhan, and Madhu S Malo, and Michael Y Choi, and Richard A Hodin
January 1963, Acta biologica et medica Germanica,
Sulaiman R Hamarneh, and Byeong-Moo Kim, and Kanakaraju Kaliannan, and Sara A Morrison, and Tyler J Tantillo, and Qingsong Tao, and Mussa M Rafat Mohamed, and Juan M Ramirez, and Aaron Karas, and Wei Liu, and Dong Hu, and Abeba Teshager, and Sarah Shireen Gul, and Konstantinos P Economopoulos, and Atul K Bhan, and Madhu S Malo, and Michael Y Choi, and Richard A Hodin
December 1980, European journal of biochemistry,
Sulaiman R Hamarneh, and Byeong-Moo Kim, and Kanakaraju Kaliannan, and Sara A Morrison, and Tyler J Tantillo, and Qingsong Tao, and Mussa M Rafat Mohamed, and Juan M Ramirez, and Aaron Karas, and Wei Liu, and Dong Hu, and Abeba Teshager, and Sarah Shireen Gul, and Konstantinos P Economopoulos, and Atul K Bhan, and Madhu S Malo, and Michael Y Choi, and Richard A Hodin
November 2018, Journal of lipid research,
Copied contents to your clipboard!